An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine.

Trial Profile

An Open-label, Single-sequence Study in Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP1A2 Inhibitor, Fluvoxamine.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2012

At a glance

  • Drugs Fluvoxamine; Tasimelteon
  • Indications Circadian rhythm sleep disorders; Insomnia; Major depressive disorder; Obsessive-compulsive disorders; Social phobia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 09 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 06 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top